title: Is rituximab effective in acquired von Willebrand syndrome?
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Mazoyer
authors.forename: Olivier
authors.initials: O
authors.lastname: Fain
authors.forename: Robin
authors.initials: R
authors.lastname: Dhote
authors.forename: Yves
authors.initials: Y
authors.lastname: Laurian
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D000069283:Rituximab; D017211:Treatment Failure; D014842:von Willebrand Diseases / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab